Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NeurAxon reports positive Phase I data for migraine treatment
NXN-188 is a first-in-class, dual-action, small molecule that is being developed for the treatment of acute migraine and which incorporates both 5-HT agonism (the mechanism of action of
NXN-188 is a first-in-class, dual-action, small molecule that is being developed for the treatment of acute migraine and which incorporates both 5-HT agonism (the mechanism of action of
According to the company, results showed that administration of oral Adentri for 10 days, in addition to standard heart failure therapy, was well tolerated and resulted in clinically
The agreement gives Argentis the rights to the treatment, as well as the processes involved in manufacturing the pharmaceutical product. Systemic sclerosis (SSc or systemic scleroderma) is an
On February 8, 2007 in laboratories at the University of Navarra, Pamplona, Spain, professor Jose Obeso transplanted the subject, a healthy monkey, with BrainStorm’s human bone marrow derived
The vaccination is part of the continued research for Sinovac’s Phase I clinical trial of whole viron H5N1 vaccine and the beginning of its Phase I clinical trial
This will be the first such facility built on Pfizer’s 28-acre brownfield site at Shanbally. The facility will accommodate a production plant, laboratories, administration and associated infrastructure. Jacobs
These designations are based on a recommendation from the Committee for Orphan Medicinal Products of the European Medicines Agency (EMEA) and follow the previously announced orphan drug designation
Under the terms of the agreement, Icagen and Pfizer will combine resources to identify compounds that target these three ion channels in a global R&D collaboration. The companies
The approved product labeling recommends that Ranexa be initiated at 500mg twice daily and increased to 1000mg as needed, based on clinical symptoms. Prior to the launch of
Epix says that through using its proprietary, integrated computational-medicinal chemistry approach to drug discovery, it has identified three lead candidates that will move forward into lead optimization in